The rapid cost declines associated with gene editing and gene synthesis are turbo-charging scientific creativity, enabling the testing of hypotheses that, until now, have been cost-prohibitive, ARK Invest wrote in a recent newsletter. Scientists at Nationwide Children’s Hospital recently published a proof-of-concept study demonstrating that gene therapies might deliver cancer immunotherapies more effectively than the [...] The post Opportunities Emerge From Rapid Cost Declines in Gene Editing and Synthesis appeared first on ETF Trends .